QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Signal Evaluation of DPP-4 Inhibitors and Bullous Pemphigoid

Test your understanding of the concepts covered by Signal Evaluation: DPP-4 Inhibitors and Bullous Pemphigoid.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A 76-year-old patient develops biopsy-supported bullous pemphigoid after 14 months of DPP-4 inhibitor exposure and improves after discontinuation and corticosteroid treatment. What is the most appropriate professional conclusion?

The case is definitely unrelated because age is a risk factor The case is definitively caused by the DPP-4 inhibitor because improvement followed withdrawal The case contains supportive evidence but requires consideration of background risk, concomitant treatment and alternative explanations The case cannot be assessed because rechallenge is absent

Question 2 of 10 What does a positive disproportionality result for a DPP-4 inhibitor and bullous pemphigoid indicate?

The event occurs at a defined incidence among exposed patients The drug-event combination is reported more frequently than expected in the database The drug has been proven to cause the event biologically The drug has a higher true incidence than every other medicine in its class

Question 3 of 10 Why is it inappropriate to assume automatically that bullous pemphigoid is an identical class effect for all DPP-4 inhibitors?

Medicines in the same pharmacological class can never share adverse reactions Evidence may differ by molecule because of pharmacology, prescribing populations, exposure duration, reporting and study power A class effect can only be assessed using individual case reports Regulatory action for one active substance excludes all class-level interpretation

Question 4 of 10 Why is a precise clinical case definition particularly important when evaluating a signal for bullous pemphigoid?

It eliminates the need to investigate confounding It ensures that all skin reactions are included in the analysis It reduces mixing of true bullous pemphigoid with nonspecific blistering conditions It allows spontaneous reports to provide a denominator

Question 5 of 10 Which factor could produce high disproportionality without necessarily indicating a higher underlying biological risk?

Stimulated reporting following regulatory attention A known denominator from a prospective cohort Randomisation with balanced treatment groups Confirmed absence of reporting bias

Question 6 of 10 Which combination would make an individual suspected bullous pemphigoid case particularly informative for signal evaluation?

A nonspecific rash with no diagnostic testing or treatment information A well-documented diagnosis supported by dermatological investigations and a plausible chronology A case reported after media coverage without information on exposure duration A case with a positive rechallenge performed intentionally in clinical practice

Question 7 of 10 Which statement best describes the evidential meaning of improvement after discontinuation of a suspected DPP-4 inhibitor in a bullous pemphigoid case?

It proves that the medicine caused the disease It is irrelevant because bullous pemphigoid cannot improve after treatment changes It can support causality but must be interpreted alongside disease fluctuation and other interventions It establishes the absolute risk for the drug class

Question 8 of 10 Which statement best distinguishes biological plausibility from an established mechanism in this signal?

DPP-4/CD26 has immune-related functions, providing plausibility, but one definitive pathway linking inhibition to all cases has not been established Because DPP-4 is involved in glucose metabolism, immune effects are impossible A plausible immune pathway proves the epidemiological association is causal Mechanistic evidence is unnecessary once a disproportionality signal is detected

Question 9 of 10 What is the main reason prevalent-user studies may underestimate early adverse events associated with a medicine?

Prevalent users have already survived and tolerated treatment for some period Prevalent users are never exposed to the medicine Prevalent-user studies cannot measure outcomes Prevalent users are always younger than new users

Question 10 of 10 Why is neurological disease relevant when evaluating the DPP-4 inhibitor and bullous pemphigoid signal?

Neurological disease can be independently associated with bullous pemphigoid and differ between treatment groups Neurological disease prevents any diagnosis of bullous pemphigoid Neurological disease is an established mechanism of DPP-4 inhibition Neurological disease makes cohort studies unnecessary

QPPV.com

Knowledge Assessment: Signal Evaluation of DPP-4 Inhibitors and Bullous Pemphigoid

Cookie Settings